Endocrine Abstracts

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Our objective was to describe the characteristics of these patients and their glycemic control expressed as HbA1c and times in range. Methods and patientsObservational longitudinal clinical study between January 2021 and December 2021 in patients with DM1 between 14 and 18 years. Results 95 patients included. Mean age: 16.64 ± 1.25 years, with a mean DM evolution time of 6.46 ± 3.93 years. 47.4% women. Mean HbA1c 7.81 ± 1.77%. FGM metrics: 54.17 ± 21.25% time in range, 23.61 ± 9.72% time between 180-250 mg/dl, 17.05 ± 18.26% time above 250 mg/dl, 4.21 ± 4.09% time between 54-70 mg/dl, 1.06 ± 2.21% time below 54 mg/dl. Glycemic CV 38.14 ± 7.45%. Classically, patients with a HbA1c below 7% were described as well-controlled patients. 32.6% of patients in our series achieved this target. Nowadays, among users of FGM, those categorized as well-controlled patients have to achieve a TIR>70%, TAR <25% and a TBR<4% with a CV <33% along with an use>70% of time. 9.5% of patients in our series achieved this target. Conclusion‐ In our series, there are more patients categorized as well-controlled using HbA1c < 7% (32.6%) than using the FGM metrics (9.5%).‐ FMI has revealed that using HbA1c is not enough to achieve a good glucose control in our patients.